<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical Benefit on FinanClub</title>
    <link>https://finan.club/tags/clinical-benefit/</link>
    <description>Recent content in Clinical Benefit on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 11 Apr 2024 09:02:25 +0000</lastBuildDate><atom:link href="https://finan.club/tags/clinical-benefit/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GERN</title>
      <link>https://finan.club/us/gern/</link>
      <pubDate>Thu, 11 Apr 2024 09:02:25 +0000</pubDate>
      
      <guid>https://finan.club/us/gern/</guid>
      <description>score:178
Chances: Geron Corporation has received positive regulatory and study updates, indicating potential growth in the near future. The FDA&amp;rsquo;s potential expansion of use for Geron&amp;rsquo;s multiple myeloma cell therapies and Pfizer&amp;rsquo;s gene therapy work could lead to increased market opportunities. The FDA&amp;rsquo;s backing of Geron&amp;rsquo;s pipeline candidate, imetelstat, for the treatment of transfusion-dependent anemia is a significant positive development.</description>
    </item>
    
  </channel>
</rss>
